Cryoport and European Mouse Mutant Archive Enter into Global Agreement to Provide Full-Service Logistics Solutions for Frozen Biomaterials

Critical frozen logistics solution supports shipments of mouse mutant lines to EMMA clients in more than 40 different countries with a focus on Europe and Northern America

LAKE FOREST, Calif., April 1, 2014 /PRNewswire/ -- Cryoport, Inc. (OTCBB: CYRX), the only end-to-end cryogenic logistics solutions provider, today announced that it has entered into an agreement with the European Mouse Mutant Archive("EMMA"), a part of INFRAFRONTIER, the European Research Infrastructure for phenotyping and archiving of model mammalian genomes. Under the agreement, the partners of the EMMA and their global clients will be able to ship frozen biomaterials using Cryoport's purpose-built cryogenic logistics solutions. 

Cryoport, Inc. Logo

Cryoport's solutions include dry vapor liquid nitrogen Cryoport Express® Shippers; the CryoportalTM, a robust, cloud-based logistics management platform; and cold chain logistics expertise that provides around-the-clock client support. Cryoport's solutions substantially reduce "process nuisance" as well as the cost of ordering, using, and temporarily storing cell-based biologic products at validated cryogenic temperatures. At the core, Cryoport's solutions eliminate the need for hazardous dry ice and/or capital investments in cryogenic containers; significantly reduce the risk of degradation of shipped biomaterials; tracks shipments throughout the process with intervention capability in time of need; and provide vital custody and condition information.

EMMA, a non-profit repository for the collection, archiving (via cryopreservation) and distribution of relevant mutant mouse strains essential for basic biomedical research, provides its mouse mutant resources to biomedical researchers worldwide and currently holds about 4,400 mutant mouse lines. Since its inception in 2000, the number of mutant mouse strains submitted to EMMA and the number of requests has steadily increased. To date, EMMA has shipped approximately 3,500 mouse mutant lines to clients in more than 40 different countries with a focus on Europe and Northern America.

Prof. Martin Hrabe de Angelis, EMMA Director, stated, "Cryoport's solutions will allow us to overcome the challenge of biomaterial degradation during shipment around the world, as it ensures a constant cryogenic environment. As a result, this advanced solution will ensure our customers receive material for their research that meets our stringent guidelines."

Dr. Martin D. Fray, MRC Harwell, stated, "In our experience, Cryoport offers an excellent solution that we can rely on when distributing frozen embryos and sperm around the world. Using Cryoport's turn-key cryogenic solution instead of our own equipment has streamlined our operation and introduced some real efficiencies."

"We are excited to have EMMA implement our cryogenic logistics solutions to support shipments of biomaterials to their partners around the world, including the many well-known academic facilities," stated Jerrell Shelton, Cryoport's Chief Executive Officer. "Through this agreement with EMMA, Cryoport will be improving its foothold in the European market with exposure to a broad customer base."

The European Mouse Mutant Archive ("EMMA")
The EMMA is a non-profit repository for the collection, archiving (via cryopreservation) and distribution of relevant mutant mouse strains essential for basic biomedical research. The laboratory mouse is one of the most important mammalian models for studying genetic and multi-factorial diseases in man. The comprehensive physical and data resources of EMMA support basic biomedical and preclinical research, and the available research tools and mouse models of human disease offer the opportunity to develop a better understanding of molecular disease mechanisms and may provide the foundation for the development of diagnostic, prognostic and therapeutic strategies. EMMA is supported by the partner institutions, national research programs and by the EC's FP7 Capacities Specific Program

INFRAFRONTIER is the European Research Infrastructure for phenotyping and archiving of model mammalian genomes. The INFRAFRONTIER Research Infrastructure provides access to first-class tools and data for biomedical research, and thereby contributes to improving the understanding of gene function in human health and disease using the mouse model.

The core services of INFRAFRONTIER comprise the systemic phenotyping of mouse mutants in the participating mouse clinics, and the archiving and distribution of mouse mutant lines by the European Mouse Mutant Archive (EMMA). In addition, INFRAFRONTIER provides specialized services such as the generation of germ-free mice (axenic service) and training in state of the art cryopreservation and phenotyping technologies.

The INFRAFRONTIER GmbH coordinates the transnational activities of the national partners that together form the European INFRAFRONTIER Research Infrastructure.

About Cryoport, Inc.
Cryoport provides leading edge frozen logistics solutions to the life sciences industry through the combination of purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. Its competencies range from skilled, total turnkey management of the entire life sciences cold chain logistics process to complex total management solutions for outsourced cold chain logistics.

Its packaging, built around its Cryoport Express® liquid nitrogen dry vapor shippers, is validated to maintain a constant -150°C temperature for a 10-plus day dynamic shipment duration. Its information technology boast a Cryoportal™ Logistics Management Platform which manages the entire shipment process, including initial order input, document preparation, customs clearance, integrator/courier management, shipment tracking, issue resolution, and delivery. Cryoport uses recyclable and reusable components providing an environmentally friendly solution. Cryoport solutions can record the "chain of condition" and "chain of custody" for shipments thereby meeting the exacting requirements for scientific work and for regulatory purposes. For more information, visit

Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Cryoport Investor Contacts:
Todd Fromer / Garth Russell /
P: 1 212-682-6300

Photo -

SOURCE Cryoport, Inc.